Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

ClinicalTrials.gov ID: NCT00826241

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00826241. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.

Study identification

NCT ID: NCT00826241
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Enrollment: 58 participants

Conditions and interventions

Conditions

Interventions

Temozolomide Drug
Lapatinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2009 (Actual)
Primary completion: Jul 31, 2018 (Actual)
Completion: Jul 31, 2018 (Actual)
Last update posted: Mar 22, 2019

2009 – 2018

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of California, San Francisco	San Francisco	California	94143	—
Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
University of Pittsburgh Medical Center - Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
University of Wisconsin School of Medicine and Public Health	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00826241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 22, 2019 · Synced Nov 15, 2026